<DOC>
	<DOCNO>NCT00103545</DOCNO>
	<brief_summary>The purpose study use immunologic approach follow treatment recurrent disease patient ovarian , fallopian tube , peritoneal cancer .</brief_summary>
	<brief_title>Use ACA 125 Patients With Ovarian Cancer : Safety Immune Response</brief_title>
	<detailed_description>Patients epithelial ovarian , fallopian tube peritoneal cancer receive surgical cytoreduction platinum/taxane contain chemotherapy significant chance enter complete clinical remission 70 % eventually relapse . Many patient respond additional cytotoxic treatment partial complete response , yet approximately 100 % patient ultimately progress . Novel consolidation strategy follow treatment recurrent disease need immunologic approach attractive option .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Patients epithelial carcinoma arise ovary , fallopian tube peritoneum , stag IIV . These patient must receive initial surgery chemotherapy least one platinum base chemotherapy regimen . Patients must relapse complete chemotherapy recurrent disease within last 6 week . Eligible patient may asymptomatic residual measurable disease CT scan , and/or may elevate CA125 , may complete clinical remission . Patients must adequate hematologic , renal hepatic function . Patients active malignancy concomitantly Patients within 3 week prior cytotoxic investigational chemotherapy Patients within 4 week prior radiotherapy Patients within 6 week prior immunotherapy Patients receive prior anticancer vaccine</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>ACA 125</keyword>
	<keyword>6 9 vaccination</keyword>
	<keyword>immune response</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Peritoneal cancer</keyword>
</DOC>